Dicot Pharma AB OMXSTO:DICOT:
Q3 EARNINGS AFTER FINANCIAL ITEMS AT SEK -16.1 MILLION
Dicot Pharma Q3 Loss After Financial Items SEK 16.1 Mln
Earlier from Dicot Pharma
- DICOT: Phase 2a study enrollment completed; strong cash position supports next development steps
- DICOT: Strong warrant uptake and robust cash position support ongoing LIB-01 clinical progress
- Dicot Pharma's TO 6 subscribed at 96% and provides the company SEK 43.8 million
- DICOT: LIB-01 advanced in clinical trials, secured funding, and expanded IP, positioning for growth
- Dicot Pharma granted new patent in the USA
Later from Dicot Pharma
- Dicot Pharma Submits Patent Application For LIB-01
- Dicot Pharma Signs Agreement With CRO Ahead Of Phase 2B Study With Lib-01
- Dicot Pharma to present at the Oppenheimer 36th Healthcare Life Sciences Conference
- DICOT: LIB-01 demonstrated long-lasting efficacy in phase 2a, supporting further clinical development
- Dicot Pharma initiates tablet manufacturing ahead of phase 2b clinical study
Follow Dicot Pharma into a list and get an email when it puts out news.
Follow Dicot Pharma